ASCO 2015 – WCMC Related Abstracts

In two weeks the 2015 meeting of the American Society of Clinical Oncology (ASCO) will take place in Chicago, bringing oncology professionals together from around the world. Below are the abstracts Lymphoma Program team members were involved in whole or in part to be presented at ASCO 2015:

CLL
Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation

Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL).

Follicular Lymphoma
A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma

Non-Hodgkin Lymphoma
AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R2) versus placebo plus rituximab 

Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/ALLIANCE 

Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials

A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma 

Waldenstrom’s Macroglobulinemia
Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM)

Please look to this space for further updates about developments in ASCO 2015.

REDLAMP 4: Circulating Tumor DNA & CT Monitoring for Untreated DLBCL – A Correlative Biomarker Study

First-line chemotherapy for diffuse large B-cell lymphoma is given with curative intent, but is not always effective. In this video, Dr. Peter Martin discusses the implications of a recently published study in Lancet Oncology, which aimed to discover whether a blood test capable of detecting circulating tumor DNA might predict treatment success or failure. In the future, blood tests may be added to, or even replace, current standard surveillance methods like CT scans or PET scans.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2074.

Dr. John Leonard Comments on Fox 5 News Regarding the Importance of Clinical Trials

Via the Meyer Cancer Center.

Recently Fox 5 News interviewed Lymphoma Program director, Dr. John Leonard about patient participation in clinical trials. As the director of the Joint Clinical Trials Office at Weill Cornell Medical College and NewYork-Presbyterian Hospital, Dr. Leonard is an expert in all questions relating to clinical trials. In the video Dr. Leonard cautioned that,

“…finding patients for clinical trials is often about numbers not money. Dr. Leonard says his office is trying to get the word out and let more patients know that clinical studies are out there that than can potentially help them.

Dr. Leonard’s office focuses on finding more effective treatments for serious illnesses like cancer and neurological disorders. He says it is a great opportunity for patients to gain access to the newest treatments before they’re available to anyone else.

Dr. Leonard has personally treated patients on clinical trials who have been among the first people to ever get a drug, and also among the first people to be effectively treated, cured, or had a better outcome because they participated in a clinical trial.

Remember, there is a big difference between answering an online ad for a medical study and going to a reputable institution like Weill Cornell Medical College or New York Presbyterian Hospital.

You can see plenty of cautionary tales online from people who signed up for studies online and gave their personal information only to find out that study was a scam designed to get and sell that personal information to marketers.

If you think a clinical trial might work for you, Dr. Leonard suggests contacting your physician.”

If you are interested in participating in a clinical trial for patients with lymphoma at Weill Cornell Medical College please click on the link.

Dr. John Leonard can be followed on Twitter @JohnPLeonardMD.

The Lymphoma Program can be followed on Twitter @lymphomaprogram.